CSL completed construction in September of 2022 on its $150 million R&D campus in Marburg, Germany. Located in the Görzhausen Industrial Park, the 430,000-sf facility offers sophisticated environments for the creation of next-generation mRNA vaccines, recombinant technologies, and cell and gene therapies. Accommodating up to 500 employees, the multidisciplinary complex represents CSL’s largest global research hub with 75,000 sf of lab space and 75,000 sf of office space. Integrated collaboration venues foster shared discovery with academic and industry partners, augmented by an 8,500-sf business incubator to accelerate the growth of startup companies. The project adheres to the United Nations Sustainable Development Goals as well as meeting the strict criteria required by KfW Group’s Green Bond funding program. Advanced infrastructure including heat pumps and an ice storage system will enable highly efficient building operations. Construction began in November 2019 and occupancy is expected in late 2022.
CSL (Commonwealth Serum Laboratories) was established in Australia in 1916. Today, the company's businesses include CSL Behring, a global leader in rare and serious diseases, influenza vaccine manufacturer CSL Seqirus, and plasma collection company CSL Plasma. The recently formed CSL Vifor develops innovative solutions for iron deficiency and nephrology.
